Thursday, July 17, 2008

An Ovation for Medivation

More good news on the Alzheimer's treatment front today. New research released today and being published in The Lancet demonstrates a significant improvement in people with Alzheimer's taking the drug Dimebon. Patients showed a substantial reduction in Alzheimer's symptoms after 6 months on Dimebon, and even more improvements at 12 months. Dimebon maker Medivation said they hope to have the drug to market in the US in 2010. The drug is also being investigated as a treatment for Huntington's Disease. If you or a loved are affected by Alzheimer's and are interested in enrolling in clinical drug trials, please visit The Connection Study today.Sphere: Related Content

No comments:

Custom Search